Literature DB >> 34395807

Retroviral Capsid Core Stability Assay.

Tyler Milston Renner1, Kasandra Bélanger1, Marc-André Langlois1.   

Abstract

Structural stability of the capsid core is a critical parameter for the productive infection of a cell by a retrovirus. Compromised stability can lead to premature core disassembly, exposure of replication intermediates to cytosolic nucleic acid sensors that can trigger innate antiviral responses, and failure to integrate the proviral genome into the host DNA. Thus, core stability is a critical feature of viral replicative fitness. While there are several well-described techniques to assess viral capsid core stability, most are generally time and labor intensive. Recently, our group compared the relative stability of murine leukemia virus capsid cores using an in vitro detergent-based approach combined with ultracentrifugation against the popular fate of capsid assay. We found that both methods reached similar conclusions, albeit the first method was a significantly simpler and faster way to assess relative capsid core stability when comparing viral mutants exhibiting differences in core stability.
Copyright © 2018 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Capsid core stability assay; Enveloped virus; Fate of capsid assay; Glycosylated Gag; HIV; MLV; Retrovirus; TRIM5α; gPr80

Year:  2018        PMID: 34395807      PMCID: PMC8328634          DOI: 10.21769/BioProtoc.3019

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  19 in total

1.  The stoichiometry of Gag protein in HIV-1.

Authors:  John A G Briggs; Martha N Simon; Ingolf Gross; Hans-Georg Kräusslich; Stephen D Fuller; Volker M Vogt; Marc C Johnson
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

2.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.

Authors:  Matthew Stremlau; Michel Perron; Mark Lee; Yuan Li; Byeongwoon Song; Hassan Javanbakht; Felipe Diaz-Griffero; Donovan J Anderson; Wesley I Sundquist; Joseph Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-15       Impact factor: 11.205

Review 3.  HIV-1 capsid: the multifaceted key player in HIV-1 infection.

Authors:  Edward M Campbell; Thomas J Hope
Journal:  Nat Rev Microbiol       Date:  2015-08       Impact factor: 60.633

4.  Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Cindy Lam; María Carla Rosales Gerpe; Joanne Eileen McBane; Marc-André Langlois
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  In vitro uncoating of HIV-1 cores.

Authors:  Vaibhav B Shah; Christopher Aiken
Journal:  J Vis Exp       Date:  2011-11-08       Impact factor: 1.355

6.  Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

Authors:  Brett M Forshey; Uta von Schwedler; Wesley I Sundquist; Christopher Aiken
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid.

Authors:  Michel J Perron; Matthew Stremlau; Mark Lee; Hassan Javanbakht; Byeongwoon Song; Joseph Sodroski
Journal:  J Virol       Date:  2006-11-29       Impact factor: 5.103

8.  Cell-free assays for HIV-1 uncoating.

Authors:  Christopher Aiken
Journal:  Methods Mol Biol       Date:  2009

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

10.  The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1.

Authors:  Nan Yan; Ashton D Regalado-Magdos; Bart Stiggelbout; Min Ae Lee-Kirsch; Judy Lieberman
Journal:  Nat Immunol       Date:  2010-09-26       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.